Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma

Lung Cancer

Volumn 56, Issue 3, 2007, Pages 327-336

  Opitz, I ^a   Sigrist, B ^a   Hillinger, S ^a   Lardinois, D ^a   Stahel, R ^a   Weder, W ^a   Hopkins Donaldson, S ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Malignant pleural mesothelioma; Necrosis; Povidone iodine; Taurolidine

Indexed keywords

ACETYLCYSTEINE; CASPASE; CISPLATIN; POVIDONE IODINE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SCAVENGER; SMALL INTERFERING RNA; SURVIVIN; TAUROLIDINE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL GROWTH; CHEMOSENSITIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INCUBATION TIME; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NECROSIS; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR CELL;

ANTI-INFECTIVE AGENTS, LOCAL; ANTINEOPLASTIC AGENTS; BIOPSY; BLOTTING, WESTERN; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MESOTHELIOMA; MITOCHONDRIAL MEMBRANES; PLEURAL NEOPLASMS; POVIDONE-IODINE; REACTIVE OXYGEN SPECIES; TAURINE; THIADIAZINES;

EID: 34247642112     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.01.024     Document Type: Article

References (35)

1. Peto J., Decarli A., La Vecchia C., et al. The European mesothelioma epidemic. Br J Cancer 79 3-4 (1999) 666-672
2. Weder W., Kestenholz P., Taverna C., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22 17 (2004) 3451-3457
3. Knight B., Skellern G., Smail G., et al. NMR studies and GC analysis of the antibacterial agent taurolidine. J Pharm Sci 72 6 (1983) 705-707
4. Calabresi P., Goulette F.A., and Darnowski J.W. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 61 18 (2001) 6816-6821
5. Bedrosian I., Sofia R.D., Wolff S.M., and Dinarello C.A. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 3 6 (1991) 568-575
6. Nici L., Monfils B., and Calabresi P. The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 10 22 (2004) 7655-7661
7. Opitz I., Veen H.C.V.D., Braumann C., et al. The influence of adhesion prophylactic substances and taurolidine/heparin on local recurrence and intraperitoneal tumor growth after laparoscopic-assisted bowel resection of colon carcinoma in a rat model. Surg Endosc 17 7 (2003) 1098-1104
8. Koldehoff M., and Zakrzewski J.L. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents 24 5 (2004) 491
9. Gainant A. Prevention of anastomotic dehiscence in colorectal surgery. J Chir (Paris) 137 1 (2000) 45-50
10. Schneiter D., Cassina P., Korom S., et al. Accelerated treatment for early and late postpneumonectomy empyema. Ann Thorac Surg 72 5 (2001) 1668-1672
11. Selvaggi G., Monstrey S., Van Landuyt K., et al. The role of iodine in antisepsis and wound management: a reappraisal. Acta Chir Belg 103 3 (2003) 241-247
12. Gottardi W. Iodine and Iodine Compounds (1991), Lea and Fibiger, Philadelphia pp. 152-166
13. Basha G., Penninckx F., and Yap P. Influence of blood components and faeces on the in vitro cancericidal activity of povidone-iodine. Br J Surg 85 4 (1998) 534-537
14. Wutzler P., Sauerbrei A., Klocking R., et al. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res 54 2 (2002) 89-97
15. Neuhaus S.J., Watson D.I., Ellis T., et al. Influence of cytotoxic agents on intraperitoneal tumor implantation after laparoscopy. Dis Colon Rectum 42 1 (1999) 10-15
16. Schmitter D., Lauber B., Fagg B., and Stahel R. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51 2 (1992) 296-301
17. Hoang C.D., D'Cunha J., Kratzke M.G., et al. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125 5 (2004) 1843-1852
18. Ke Y., Reddel R.R., Gerwin B.I., et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol 134 5 (1989) 979-991
19. Olie R.A., Simoes-Wust A.P., Baumann B., et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60 11 (2000) 2805-2809
20. Ahuja D., Saenz-Robles M.T., and Pipas J.M. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24 52 (2005) 7729-7745
21. Rodak R., Kubota H., Ishihara H., et al. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 102 6 (2005) 1055-1068
22. Keyse S.M., and Tyrrell R.M. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 86 1 (1989) 99-103
23. Ueda S., Masutani H., Nakamura H., et al. Redox control of cell death. Antioxid Redox Signal 4 3 (2002) 405-414
24. Spierings D., McStay G., Saleh M., et al. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science 310 5745 (2005) 66-67
25. Hopkins-Donaldson S., Belyanskaya L.L., Simoes-Wust A.P., et al. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 8 7 (2006) 551-559
26. Soini Y., Kinnula V., Kaarteenaho-Wiik R., et al. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5 11 (1999) 3508-3515
27. Steele J.P.C., and Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 16 3 (2005) 345-351
28. McCourt M., Wang J., Sookhai S., and Redmond H. Taurolidine inhibits tumor cell growth in vitra and in vivo. Ann Surg Oncol 7 9 (2000) 685-691
29. Proskuryakov S.Y., Konoplyannikov A.G., and Gabai V.L. Necrosis: a specific form of programmed cell death?. Exp Cell Res 283 1 (2003) 1-16
30. Ueda S., Nakamura H., Masutani H., et al. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol 161 12 (1998) 6689-6695
31. Baker A., Santos B.D., and Powis G. Redox control of caspase-3 activity by thioredoxin and other reduced proteins. Biochem Biophys Res Commun 268 1 (2000) 78-81
32. Falleni M., Pellegrini C., Marchetti A., et al. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 48 2 (2005) 211
33. Xia C., Xu Z., Yuan X., et al. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 1 9 (2002) 687-694
34. Hopkins-Donaldson S., Cathomas R., Simoes-Wust A., et al. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 106 2 (2003) 160-166
35. Braumann C., Henke W., Jacobi C.A., and Dubiel W. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer 112 2 (2004) 225-230